JBJames P. Bradley

James P. Bradley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James P. Bradley has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining Outcomes in Facial Gender-Affirming Surgery: A Systematic Review to Inform Core Outcome Set Development

    by Meghan N. Miller, Derrick Lin, Samantha Rabinovich, Graysen Airth, Sabrina Rainsbury-Silva, Rebecca Canfield, Sarah K. Fadich, Kaavian Shariati, James P. Bradley, Justine C. Lee

    Facial gender-affirming surgery (FGAS) is a transformative step for transgender individuals in their gender care journey. Even so, the way outcomes are measured and reported is highly inconsistent and unstudied. This limits the ability to compare studies or develop clear, patient-centered benchmarks for success. We systematically assess how current research defines FGAS outcomes and lay the groundwork for a unified Core Outcome Set (COS). A systematic review was conducted following the PRISMA 2020 guidelines. PubMed was searched up to 15 March 2025; we identified 334 studies, and four reviewers independently screened the studies. After screening, 207 studies met the inclusion criteria, encompassing 30,937 patients. Data on study characteristics, surgical procedures, outcome domains, measurement tools, and follow-up duration were extracted. Descriptive statistics and chi-square analyses were used to evaluate reporting trends. Most studies emphasized aesthetic outcomes (60.56%) and complications (62.44%); fewer addressed psychosocial well-being (43.19%), quality of life (35.21%), or reoperation rates (21.60%). Only 26 of the 207 studies used validated outcome instruments, such as FACE-Q or PROMIS (p < 0.001). Among studies that reported satisfaction, only 41.2% provided numerical or stratified scores. Outcome reporting in FGAS research is fragmented and dominated by subjective or unvalidated assessments. A standardized COS is needed to unify research practices, facilitate meaningful comparisons, and ensure that outcomes align with patient-defined measures of surgical success.


  • Open Access

    Defining Outcomes in Facial Gender-Affirming Surgery: A Systematic Review to Inform Core Outcome Set Development

    by Meghan N. Miller, Derrick Lin, Samantha Rabinovich, Graysen Airth, Sabrina Rainsbury-Silva, Rebecca Canfield, Sarah Fadich, Kaavian Shariati, James P. Bradley, Justine C. Lee

    Facial gender-affirming surgery (FGAS) is a transformative step for transgender individuals in their gender care journey. Even so, the way outcomes are measured and reported is highly inconsistent and unstudied. This limits the ability to compare studies or develop clear, patient-centered benchmarks for success. We systematically assess how current research defines FGAS outcomes and lay the groundwork for a unified core outcome set (COS). A systematic review was conducted following PRISMA 2020 guidelines. PubMed was searched through March 15, 2025, we identified 334 studies, and four reviewers independently screened studies. After screening, 232 studies met inclusion criteria, encompassing 30,937 patients. Data were extracted on study characteristics, surgical procedures, outcome domains, measurement tools, and follow-up duration. Descriptive statistics and chi-square analyses were used to evaluate reporting trends. Most studies emphasized aesthetic outcomes (61.6%) and complications (60.0%), fewer addressed psychosocial well-being (45.7%), quality of life (21.6%), or reoperation rates (20.7%). Only 26 of the 232 studies used validated outcome instruments, such as FACE-Q or PROMIS (p < 0.001). Among studies that reported satisfaction, only 41.2% provided numerical or stratified scores. Outcome reporting in FGAS research is fragmented and dominated by subjective or unvalidated assessments. A standardized COS is needed to unify research practices, facilitate meaningful comparisons, and ensure that outcomes align with patient-defined measures of surgical success.

  • Open Access

    Development of Normal and Cleft Palate: A Central Role for Connective Tissue Growth Factor (CTGF)/CCN2

    by Joseph T. Tarr, Alex G. Lambi, James P. Bradley, Mary F. Barbe, Steven N. Popoff

    Development of the palate is the result of an organized series of events that require exquisite spatial and temporal regulation at the cellular level. There are a myriad of growth factors, receptors and signaling pathways that have been shown to play an important role in growth, elevation and/or fusion of the palatal shelves. Altered expression or activation of a number of these factors, receptors and signaling pathways have been shown to cause cleft palate in humans or mice with varying degrees of penetrance. This review will focus on connective tissue growth factor (CTGF) or CCN2, which was recently shown to play an essential role in formation of the secondary palate. Specifically, the absence of CCN2 in KO mice results in defective cellular processes that contribute to failure of palatal shelf growth, elevation and/or fusion. CCN2 is unique in that it has been shown to interact with a number of other factors important for palate development, including bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), epidermal growth factor (EGF), Wnt proteins and transforming growth factor-βs (TGF-βs), thereby influencing their ability to bind to their receptors and mediate intracellular signaling. The role that these factors play in palate development and their specific interactions with CCN2 will also be reviewed. Future studies to elucidate the precise mechanisms of action for CCN2 and its interactions with other regulatory proteins during palatogenesis are expected to provide novel information with the potential for development of new pharmacologic or genetic treatment strategies for clinical intervention of cleft palate during development.